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Abstract The calcitonin receptor (CTR) gene in human
osteoclasts formed in a human bone marrow cell culture system
was examined by reverse transcription-polymerase chain reaction
(RT-PCR). The RT-PCR results indicated that the 5P-untrans-
lated region (5PUTR) was different between CTR mRNAs in
human osteoclasts and in a mammary tumor cell line, MCF-7
cells. We isolated the 5PUTR of the CTR gene from human
osteoclasts, whose sequence had only 28.6% identity with that of
other CTR genes reported until now. In a radioligand binding
assay, COS-1 cells transfected with the osteoclast CTR gene
bound to [125I]human CT (hCT). These results provided evidence
that the CTR gene cloned from human osteoclasts was expressed
functionally and its coding protein was identical to MCF-7 cell
CTR.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Calcitonin (CT) [1], ¢rst discovered by Copp et al. in 1962,
is a 32 amino acid polypeptide hormone that is an important
regulator of Ca2 homeostasis through its direct action on
osteoclasts inhibiting bone-resorbing activity and on renal
tubular cells where it stimulates urinary calcium excretion
[2,3]. CT also acts on other tissues, i.e. the central nervous
system [4,5], lungs [6], testes [7], placenta [8] and kidney [2].
All physiological functions of CT have yet to be determined,
but its primary role is thought to be carried out by its binding
to cell surface receptors on osteoclasts. CT has a unique abil-
ity of inhibiting bone resorption by reducing the number of
osteoclasts and their activities [9] and therefore, it is one of the
most common reagents in the clinical treatment of osteopo-
rosis [10], Paget’s disease [11] and hypercalcemia induced by
malignant tumors [12,13]. However, usage of CT has an im-
portant problem which is yet to be solved: resistance to CT
response known as the ‘escape’ phenomenon as a result of
continuous administration of the hormone [13,14]. This in£u-
ence of CT is more signi¢cant on human osteoclasts than on
cancer cell lines and on other tissue cells in human or other
species [15^18]. It is suggested that this problem may result
from a prolonged reduction of the number of CT receptors
(CTRs) on osteoclasts [19].
The initial cloning of a cDNA encoding CTR was reported
in a porcine renal cell line LLC-PK1 [20]. Since that study,
several isoforms of human CTRs (hCTRs) in tumor cell lines
have been reported: BIN-67 [21] (ovarian carcinoma), TT [22]
(medullary thyroid carcinoma), T47D [23], MCF-7 [24] (mam-
mary carcinoma) and giant cell tumor (GCT) of bone [25].
However, the CTR gene in human osteoclasts has never been
reported, mainly due to the di⁄culties in obtaining and main-
taining osteoclasts. Recently, we have established a simple and
e⁄cient system for the development of human osteoclasts in
normal bone marrow cells. This method has provided us with
numerous osteoclasts and enabled us to study the human
osteoclast gene in detail [26]. In this report, we describe the
cloning of CTR cDNA from human osteoclasts.
2. Materials and methods
2.1. Osteoclast formation
Osteoclasts were isolated from human bone marrow cells obtained
from the proximal femur at the time of arthroplasty. A monocyte-rich
fraction was isolated from bone marrow cells with Histopaque 1077
(Sigma) as described previously [27] with modi¢cations and cultured
in K-minimum essential medium (K-MEM) (Irvine Scienti¢c) supple-
mented with 20% heat-inactivated horse serum (Gibco BRL) and 1038
M 1K,25-dihydroxy vitamin D3 (kindly supplied by Teijin) for 2^3
weeks and osteoclast-like multinucleated cells (MNCs) were formed.
These MNCs possessed the osteoclast characteristics, such as multi-
nuclei, staining with tartrate resistant acid phosphatase and reduction
of bone resorption activity in response to CT [26]. The MNCs in the
culture were treated with 0.002% pronase E (Sigma)/0.02% EDTA in
phosphate-bu¡ered saline (PBS(3), pH 7.4) for 5 min to remove stro-
ma cells and adherent osteoclasts were cultured overnight and used
for extraction of total RNA.
2.2. Preparation of total RNA from human osteoclasts and reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA from human osteoclasts was extracted by the acid gua-
nidinium-phenol-chloroform method [28]. Reverse transcription (RT)
of total RNA to cDNA and subsequent ampli¢cation (PCR) were
accomplished using reagents from TaKaRa LA PCR kit (AMV)
Ver.1.1 (TaKaRa biomedicals). Synthesized primers were shown in
Fig. 1. 4.5 Wg of total RNA was reverse-transcribed by AMV reverse
transcriptase for 10 min at 30‡C, followed by 1 h at 42‡C. The reac-
tion was terminated by heating for 5 min at 99‡C, followed by chilling
to 4‡C. RT samples were used for PCR. After the reaction was heated
at 94‡C for 2 min, 55 cycles of denaturation for 30 s at 94‡C, anneal-
ing for 30 s at 55‡C and extension for 2 min at 72‡C were performed
in a Perkin-Elmer/Cetus DNA thermal cycler and followed by a ¢nal
extension at 72‡C for 7 min. R2 was used as a reverse primer other-
wise mentioned.
2.3. Cloning of the 5P-untranslated region (5PUTR)
Ampli¢cation and isolation of the 5PUTRs of CTR genes in osteo-
clasts and MCF-7 cells was performed in total RNAs of both cells
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using the rapid ampli¢cation of cDNA ends (5PRACE system Ver.2.0,
Gibco BRL) method. First strand cDNA was synthesized from 1 Wg
of total RNA using gene speci¢c primer 1 (GSP1, 5P-GACCCACAA-
TAGCCAAATAG-3P). After the puri¢cation of this ¢rst strand of
cDNA, terminal deoxynucleotidyl transferase and dCTP were used
to add homopolymeric tails to the 3P-ends of the cDNA. PCR was
ampli¢ed using GSP2 (5P-CAGGAGTGAAAGCATTGCACA-3P)
and the abridged anchor primer was provided by this system. Re-
ampli¢cation of primary PCR product employed nested GSP (5P-
GCCATTTTCATAAATTGCGGGCAGC-3P) and the abridged uni-
versal ampli¢cation primer was produced with this method. The am-
pli¢ed fragments were cloned into pCR2.1 (Invitrogen) directly. The
nucleotide sequences of these clones were determined in both strands
by the dideoxy termination method.
2.4. Cloning of human osteoclast CTR cDNA
The ¢rst strand cDNA was synthesized from the isolated total
RNA with random 9-mer primers and the product was ampli¢ed
using the RNA PCR kit (AMV) Ver.2.1 (TaKaRa). The sense primers
used to amplify CTR cDNA from osteoclasts and MCF-7 cells were
5P-CCAGTGAGAAGTATGAGAGAGTG-3P and 5P-CAGGAAG-
GCGCCGGGAA-3P, respectively, and the antisense primer was 5P-
ACATTCAAGCAGATGACTCTTGCT-3P. 55 Cycles of denatura-
tion for 20 s at 95‡C, annealing for 30 s at 60‡C and extension for
1 min at 72‡C were performed in a Perkin-Elmer/Cetus DNA thermal
cycler.
2.5. Transfection of COS-1 cells with CTR cDNA including the 5PUTR
region
Ampli¢ed CTR genes from human osteoclasts and MCF-7 cells
were respectively inserted into pCR3.1 (Invitrogen) under its cytome-
galovirus promoter. pCMVOC1 and pCMVOC2 represent the expres-
sion plasmids inserted with osteoclast CTR cDNA in the sense and
antisense direction, respectively, and pCMVMC is the plasmid con-
taining CTR cDNA from MCF-7 cells in the sense direction. Mono-
layers of COS-1 cells (from the Health Science Research Resources
Bank) in 10 cm culture dishes (Corning) were prepared in 5 ml Dul-
becco’s MEM (DMEM; Gibco BRL) containing 1 g/l glucose and
2 mM L-glutamine. Cells were transfected with 28 Wg each of plasmid
using FuGENE 6 transfection reagent (Boehringer Mannheim). Cells
were incubated at 37‡C in a 5% CO2 atmosphere. 6 h after trans-
fection, 5 ml DMEM containing 10% fetal bovine serum (FBS; Irvine
Scienti¢c) was added to the medium in culture. After an additional
18 h, the medium was replaced with 10 ml DMEM/10% FBS. 48 h
after transfection, a radioligand binding assay was performed as de-
scribed below.
2.6. Binding of radiolabelled hCT to COS-1 cells
Radioligand binding assays were performed as described previously
[21] with a slight modi¢cation. In brief, COS-1 cells transfected with a
hCTR gene were washed with PBS(3) once and dispersed by trypsin-
ization. After centrifugation at 1000 rpm for 5 min, cell pellets were
suspended in a binding bu¡er and counted. A portion of 3^5U105
cells was divided into a 12U75 mm glass tube in a volume of 200 Wl of
binding bu¡er (PBS(3), pH 7.4, 11 mM glucose, 1% bovine serum
albumin) plus 200 pmol of [125I]hCT (Amersham) in the presence of a
10^105-fold molar excess of unlabelled hCT (generously supplied by
Sankyo). The incubation time was 16 h at 4‡C. Then, 100 Wl of the cell
suspension was layered over 200 Wl of 10% sucrose (w/v)-containing
binding bu¡er in a 1.5 ml microfuge tube (Bio-Rad Laboratories) and
centrifuged at 10 000 rpm for 5 min to precipitate the cells. The su-
crose and incubation bu¡er were then removed by aspiration and the
centrifuge tube containing only cells was counted for radioactivity in a
gamma counter (Aloka). Saturation ligand binding to COS-1 cells
transfected with the hCTR was performed using the same technique
in the presence or absence of a 103-fold molar excess of unlabelled
hCT with an increasing concentration of [125I]hCT. The Kd value and
the number of binding sites were calculated by Scatchard analysis.
Fig. 1. Primer sequences in RT-PCR referred to the CTR cDNA in
T47D cells. Forward primers: F1, F2, F3 and F4. Reverse primers:
R1, R2 and R3.
Fig. 2. RT-PCR analysis of CTR mRNA of human osteoclasts and
T47D cells (mammary tumor cell line) using various kinds of prim-
ers. Total RNA extracted from human osteoclasts (OC) and T47D
cells (T) was used.
Fig. 3. The nucleotide sequence of the CTR gene in human osteo-
clasts. The start and stop codons of the coding region are under-
lined. This coding region was identical to that of CTR cDNA in
the MCF-7 cells, mammary tumor cell line. Conversely, 5PUTRs
were quite di¡erent from each other with an identity of 45.0%, 143/
317 base points in the 5PUTR of osteoclast CTR cDNA as de-
scribed in Fig. 4.
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3. Results
3.1. CTR mRNA expressed in human osteoclasts
The detection of CTR mRNA expression in human osteo-
clasts was related to the forward primer used for RT-PCR
ampli¢cation (Figs. 1 and 2). When F1 or F2 was used as a
forward primer, the ampli¢ed fragment was scarcely detected.
However, we detected the ampli¢ed fragments when any of
the F3^6 primers were employed. In contrast, the ampli¢ca-
tion was independent of the reverse primer used (data not
shown). This fact implied that CTR cDNA in osteoclasts
had a common sequence with that in MCF-7 cells in the
downstream region of the start codon. However, they di¡ered
from each other in the 5PUTR. Then, we cloned both CTR
Fig. 4. The di¡erence among nucleotide sequences of 5PUTRs of CTR genes in human osteoclasts, MCF-7 cell line, rat brain, mouse brain and
porcine kidney cell line (LLC-PK1).
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cDNAs containing the 5PUTR and coding region from human
osteoclasts and MCF-7 cells. The nucleotide sequence of hu-
man osteoclast CTR cDNA was shown in Fig. 3.
The deduced coding region of CTR in human osteoclasts
was identical to that in MCF-7 cell lines, however, 45% of
5PUTRs (143/317 nucleotide base) in the osteoclast gene were
di¡erent from that in MCF-7 cells. There were no similarities
in 5PUTR of cDNAs in human osteoclasts and others, rat
brain, mouse brain and porcine kidney cell line (LLC-PK1)
(Fig. 4). The sequence identity was 72.7% between 5PUTRs of
MCF-7 and porcine cell lines, 65.5% between rat and mouse
tissues, 32.8% among these four genes and 28.6% between
these four genes and human osteoclasts, respectively.
3.2. Characteristics of binding of radiolabelled hCT to
transfected cells
Binding of [125I]hCT was assayed in triplicate for each cells
transfected with four kinds of plasmids. COS-1 cells, trans-
fected with pCMVOC1, as well as pCMVMC, bound to
[125I]hCT, whose binding decreased by the addition of a 10^
105-fold molar excess of unlabeled CT in a dose dependent
manner (Fig. 5). However, the [125I]hCT binding activity of
pCMVOC1 was less than that in pCMVMC. COS-1 cells
transfected with pCMVOC2 and with pCR3.1 (plasmid alone)
did not speci¢cally bind to [125I]CT.
A saturation binding assay showed speci¢c CTRs in osteo-
clast CTR-transfected cells (Fig. 6). Speci¢c binding to
pCMVOC1-transfected cells (Fig. 6a) was less than that in
pCMVMC-transfected cells (Fig. 6b). Scatchard analysis in-
dicated that the Kd values for hCT were similar in
pCMVOC1- (V9.74 nM) and pCMVMC-transfected COS-1
cells (V10.6 nM). Binding sites were 2.7U105 sites/cell and
6.4U105 sites/cell for pCMVOC1- and pCMVMC-transfected
cells, respectively. Expectedly, the protein structure synthe-
sized from the osteoclast CTR gene was identical to that of
the MCF-7 CTR gene, but the expression e⁄ciency di¡ered
between them.
4. Discussion
Recent studies have detected hCTR genes primarily in hu-
man tumor cell lines [21^25] and in renal tissue [29]. hCTR
isoforms have been classi¢ed into three types, where the ma-
jority is human type 1 including tumor cell lines as mentioned
above. The nucleotide sequences of CTR cDNAs in BIN-67,
T47D, MCF-7 and GCT of bone, which expresses two iso-
forms [25], indicated that 5PUTRs of CTR cDNAs were sim-
ilar (Fig. 7). Only the BIN-67 clones had an insertion of 71 bp
(between nucleotide positions 46 and 47 of the MCF-7 clones,
Fig. 5. Radioligand binding assay of hCT in COS-1 cells transfected
with CTR cDNA from human osteoclasts and MCF-7 cells. COS-1
cells transfected with four plasmids, pCR3.1 (E), pCMVOC1 (a),
pCMVOC2 (R) and pCMVMC (b) bound to [125I]hCT in the pres-
ence or absence of a 10^105-fold molar excess of unlabelled hCT.
Fig. 6. Saturation binding of [125I]hCT to COS-1 cells transfected
with pCMVOC1 (a) and pCMVMC (b) in the presence or absence
of a 103-fold molar excess of unlabelled hCT with an increasing
concentration of [125I]hCT. Total, speci¢c and non-speci¢c binding
are represented by an open symbol, closed symbol and open symbol
with dotted line, respectively. Data represent the means of triplicate
measurements and are representative of two separate experiments.
Maximum binding of pCMVOC1 was 3759 cpm per assay on aver-
age and that of pCMVMC was 8004 cpm.
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at the site of intron 2), which included a potential alternative
start codon. 5PUTRs of the two GCT clones are identical and
extend further upstream than that of the MCF-7 clones by
104 bp. The 5PUTR of the T47D clones is even shorter by 35
bp. In addition, there is just one other nucleotide in the
5PUTR: position 67 is a T in the BIN-67 clones but a C in
the clones of other cell lines. In short, there are no very re-
markable changes between 5PUTRs of cDNAs in cancer cell
lines and normal renal tissue cells [29]. On the other hand, the
5PUTR of CTR cDNA in human osteoclasts we ¢rst cloned
was quite di¡erent from that in these cDNAs.
The precise role of the distinct 5PUTR of human osteoclast
cDNA is unknown. However, the 5PUTR, as well as the
3PUTR, is recognized as an important element in the post-
transcriptional regulation of gene expression [30] and several
examples showing their importance have been reported
[31,32]. Heterogeneity in the 5PUTR of mRNAs leads to an
altered translational status of mRNAs. Our study also indi-
cated the di¡erence of translational e⁄ciency between CTR
genes from osteoclasts and from MCF-7 cells in COS-1 cells
by the di¡erence in [125I]hCT binding activity of both CTR
genes in a radioligand binding assay (Figs. 5 and 6).
A further hypothesis is that the di¡erence of 5PUTRs might
lead to that of promoter regions and that the expression of
CTR gene in human osteoclasts would be controlled by dis-
tinct promoters other than in human tumor cell lines. For
example, the PTH receptor gene, belonging to the G-pro-
tein-coupled receptors family including CTR, has at least
two promoters [33,34]. Its downstream promoter is ubiqui-
tously expressed, whereas the expression of the upstream pro-
moter is largely restricted to kidney. If there were also the
distinct promoters in the human osteoclast CTR gene, they
could down-regulate the response to human or salmon CT of
human osteoclasts both in vitro and in vivo. This ‘escape’
phenomenon is found more remarkably in human osteoclasts
than in human tumor cell lines. The cellular and molecular
mechanisms of this phenomenon are still unknown, but the
prolonged suppression of CTR mRNA has been identi¢ed in
both short and long term treatment of osteoclast-like MNCs
in mouse bone marrow culture with salmon CT [19,35].
Although the specimens in these experiments were not carried
out in human, it is still likely that the regulation of CTR
mRNA expression is probably an important process and these
regulators would be distinct promoters in human osteoclasts.
The regulation mechanism of CTR in human osteoclasts
remains to be solved. Additional research is needed to analyze
the upper-stream regions, that is, promoter and enhancer re-
gions in the CTR gene of human osteoclasts.
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